SAN FRANCISCO, Feb.23, 2021 / PRNewswire / – Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit immunosuppressive signaling pathways and promote cancer, today announced the completion of a $ 30 million Series A funding of dollars. The financing was led by Oceanpine Capital with the participation of new additional investors Oriza Ventures, Lifespan Investments and former senior executives at Gilead. All existing investors also participated in the funding round, including Northern Light Venture Capital, Kaitai Capital and Oriental Fortune Capital. The funds will be used to advance the Company’s selective A2BR antagonist TT-702 in the clinic as well as to build…
Read Additional From Source
Copyright @ finance.yahoo.com
News Highlights Finance
- Headline: Teon Therapeutics closes $ 30 million Series A financing
- Check all news and articles from the Finance news updates.